TG Therapeutics, Inc. TGTX
At closeNov 10, 2026, 7:43 PM EST
After hours · Nov 10, 7:43 PM ET
- YTD
- +115.57%
- 1 year
- +112.08%
- Market cap
- 9.84B
- Revenue (ttm)
- 897.76M
- Profit margin
- 11.81%
- EPS (ttm)
- 0.68
- Shares out
- 153.07M
- P/E ratio
- 94.50
- Forward P/E
- 24.29
- YTD return
- +115.57%
- 1-year return
- +112.08%
- Volume
- 5.79M
- Avg volume
- 1.91M
- Open
- 62.70
- Previous close
- 63.38
- Day's range
- 62.19 – 68.03
- 52-week range
- 26.94 – 64.26
- Beta
- 1.81
- Analysts
- Strong Buy
- Price target
- 69.71 (+8.5%)
- Earnings date
- Feb 25, 2027
5D +2.24 (+3.61%)
Key statistics
- Enterprise value
- 9.19B
- PEG ratio
- 1.61
- Price / sales
- 10.96
- Price / book
- 15.09
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 60.70%
- Free cash flow
- 0
- Total cash
- 552.25M
- Total debt
- 754.44M
- Return on equity
- 0.00%
- Short % of float
- 27.94%
- 50-day average
- 55.99
- 200-day average
- 44.69
Analyst view
Consensus: strong buy
- Target (low)
- 21.00
- Target (mean)
- 69.71
- Target (high)
- 86.00
- Strong buy1
- Buy6
- Hold0
- Sell0
- Strong sell1
Next earnings
Feb 25, 2027
Expected Feb 25, 2027. Consensus EPS estimate 0.60.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 25, 2027 | Dec 30, 2026 | 0.38 | — | — | — |
| Nov 9, 2026 | Sep 30, 2026 | 0.3593 | 0.35 | -0.01 | -2.59% |
| Aug 3, 2026 | Jun 30, 2026 | 0.3057 | 0.05 | -0.26 | -83.64% |
| May 6, 2026 | Mar 31, 2026 | 0.23 | 0.14 | -0.09 | -39.13% |
| Feb 26, 2026 | Dec 31, 2025 | 0.35 | 0.14 | -0.21 | -60.00% |
| Nov 3, 2025 | Sep 30, 2025 | 0.24 | 2.43 | +2.19 | +912.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 10, 2026 | Evercore ISI Group | main | Outperform | Outperform |
| Sep 1, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 7, 2026 | JP Morgan | main | Overweight | Overweight |
| Jul 27, 2026 | B. Riley Securities | main | Buy | Buy |
| Jul 13, 2026 | HC Wainwright & Co. | main | Buy | Buy |
| Jul 7, 2026 | B of A Securities | main | Underperform | Underperform |
About TG Therapeutics, Inc.
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- tgtherapeutics.com
News
TGTX Q3 Earnings & Revenues Beat Estimates, 2026 View Raised, Stock Up 
4 Commercial-Stage Biotechs Poised for Sustained Revenue Growth 
Evercore ISI Group Maintains Outperform on TG Therapeutics, Lowers Price Target to $71 
Calamos Advisors LLC Acquires New Stake in TG Therapeutics, Inc. $TGTX 
TG Therapeutics, Inc. (TGTX) Q3 2026 Earnings Call Transcript 
What TG Therapeutics (TGTX) Said on Its Q3 Earnings Call 
Hims-Eli Lilly GLP-1 Deal Meets Summit’s FDA Gamble: Which Biotech ETFs Stand to Gain? 
TG Therapeutics (TGTX) Reports Q3 Earnings: What Key Metrics Have to Say 
TG Therapeutics (TGTX) Beats Q3 Earnings and Revenue Estimates 
TG Therapeutics Q3 2026 Earnings Call Transcript
Your note
Sign in to keep a note on TGTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CHARNEY LAURENCE NEIL | Director | Sale | Sep 9, 2026 | 168,640 |
| ECHELARD YANN | Director | Sale | Nov 23, 2025 | 223,816 |
| HOBERMAN KENNETH | Director | Stock Award(Grant) | Jun 11, 2025 | 279,653 |
| HUME DANIEL | Director | Stock Award(Grant) | Jun 11, 2025 | 192,748 |
| LONIAL SAGAR | Director | Sale | Sep 10, 2025 | 94,061 |
| POWER SEAN A | Chief Financial Officer | Stock Award(Grant) | Jan 7, 2026 | 798,111 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 14.41% | 22,050,045 | 1.42B | Jun 29, 2026 |
| Vanguard Portfolio Management LLC | 5.20% | 7,963,266 | 511.72M | Jun 29, 2026 |
| State Street Corporation | 5.09% | 7,786,471 | 500.36M | Jun 29, 2026 |
| Vanguard Capital Management LLC | 4.02% | 6,149,403 | 395.16M | Jun 29, 2026 |
| Geode Capital Management, LLC | 2.42% | 3,703,676 | 238.00M | Sep 29, 2026 |
| Shaw D.E. & Co., Inc. | 2.22% | 3,400,808 | 218.54M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Trust-iShares Core S&P Small-Cap ETF | 5.52% | 8,449,942 | 542.99M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.86% | 4,377,027 | 281.27M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.46% | 3,765,888 | 242.00M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.06% | 3,160,785 | 203.11M | Jun 29, 2026 |
| SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 1.77% | 2,703,952 | 173.76M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Growth Index Fund | 1.19% | 1,820,899 | 117.01M | Jun 29, 2026 |